Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727103 · ClinicalTrials.gov registry record · Phase 4
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
A Phase 4 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00727103 is a Phase 4 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 10 participants.
The verdict
NCT00727103, a Phase 4 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The aim of the proposed pilot study is to find out whether varenicline (ChantixTM) treatment decreases alcohol use and smoking in patients with schizophrenia or schizoaffective disorder. Varenicline may also improve cognition (memory and concentration) and negative symptoms (e.g. poor attention, poverty of speech, apathy, affective flattening, anhedonia) in patients with schizophrenia and comorbid nicotine and alcohol dependence.
Interventions
- DRUG Placebo
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727103
The ClinicalTrials.gov registry entry for NCT00727103 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00727103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727103 about?
NCT00727103 is a clinical study titled "Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia". The aim of the proposed pilot study is to find out whether varenicline (ChantixTM) treatment decreases alcohol use and smoking in patients with schizophrenia or schizoaffective disorder. Varenicline may also improve cognition (memory and concentration) and negative symptoms (e.g. poor attention, pov...
What is the current status of trial NCT00727103?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2008-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00727103?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00727103?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.